Payment overview · 2025
General Payments
$379.11
22 reported records · 11 companies
Healthcare provider profile · identity verified
Hannah Ray
Allopathic & Osteopathic Physicians|Family Medicine · FLOWOOD, MS · NPI 1023404100
Verified facts
What the public records show
CMS Open Payments records show Hannah Ray received $379.11 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 32.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ubrelvy by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 313 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $123.27 | 32.5% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.52 | 12.0% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $31.17 | 8.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.11 | 7.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.28 | 7.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.87 | 7.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.30 | 5.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.98 | 5.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.66 | 4.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.27 | 4.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.68 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $379.11 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $107.62 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $107.62 | 6 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $49.80 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $31.17 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.11 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.73 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.28 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.28 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 313 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 195 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 253 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
195 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
313 | 63 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
95 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
253 | 49 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1043 | 251 |
| Amlodipine Besylate | Amlodipine Besylate | 631 | 158 |
| Gabapentin | Gabapentin | 582 | 123 |
| Furosemide | Furosemide | 548 | 123 |
| Omeprazole | Omeprazole | 443 | 108 |
| Losartan Potassium | Losartan Potassium | 388 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 343 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 341 | 78 |
| Spironolactone | Spironolactone | 320 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 319 | 81 |
| Farxiga | Dapagliflozin Propanediol | 313 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 308 | 110 |
| Potassium Chloride | Potassium Chloride | 291 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 273 | 56 |
| Famotidine | Famotidine | 270 | 56 |
| Montelukast Sodium | Montelukast Sodium | 270 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 269 | 56 |
| Metformin Hcl | Metformin Hcl | 259 | 69 |
| Ozempic | Semaglutide | 253 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 245 | 84 |
| Zolpidem Tartrate | Zolpidem Tartrate | 234 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 212 | 48 |
| Glipizide Er | Glipizide | 207 | 39 |
| Meloxicam | Meloxicam | 207 | 61 |
| Carvedilol | Carvedilol | 195 | 46 |
| Linzess | Linaclotide | 195 | 39 |
| Allopurinol | Allopurinol | 190 | 46 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 173 | 44 |
| Lisinopril | Lisinopril | 171 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 167 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 160 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 155 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 151 | 42 |
| Colchicine | Colchicine | 142 | 36 |
| Jardiance | Empagliflozin | 139 | 31 |
| Eliquis | Apixaban | 135 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 36 |
| Nifedipine Er | Nifedipine | 128 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 28 |
| Tramadol Hcl | Tramadol Hcl | 124 | 33 |
| Clonidine Hcl | Clonidine Hcl | 123 | 19 |
| Valsartan | Valsartan | 122 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 121 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 121 | 32 |
| Ezetimibe | Ezetimibe | 120 | 26 |
| Celecoxib | Celecoxib | 118 | 24 |
| Alprazolam | Alprazolam | 116 | 30 |
| Xarelto | Rivaroxaban | 116 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 28 |
| Alendronate Sodium | Alendronate Sodium | 113 | 21 |
| Pregabalin | Pregabalin | 113 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 109 | 16 |
| Meclizine Hcl | Meclizine Hcl | 107 | 30 |
| Entresto | Sacubitril/Valsartan | 106 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 106 | 30 |
| Atenolol | Atenolol | 105 | 20 |
| Prednisone | Prednisone | 103 | 63 |
| Diclofenac Sodium | Diclofenac Sodium | 101 | 28 |
| Metformin Hcl Er | Metformin Hcl | 96 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 95 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 95 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 92 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 85 | 22 |
| Ibuprofen | Ibuprofen | 85 | 31 |
| Lovastatin | Lovastatin | 84 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 82 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 15 |
| Myrbetriq | Mirabegron | 69 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 67 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 16 |
| Januvia | Sitagliptin Phosphate | 64 | 17 |
| Mounjaro | Tirzepatide | 64 | suppressed |
| Trulicity | Dulaglutide | 64 | 16 |
| Glipizide | Glipizide | 63 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 59 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 59 | 12 |
| Baclofen | Baclofen | 56 | 13 |
| Donepezil Hcl | Donepezil Hcl | 56 | 14 |
| Estradiol | Estradiol | 56 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 56 | 19 |
| Glimepiride | Glimepiride | 53 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 53 | 16 |
| Buspirone Hcl | Buspirone Hcl | 52 | suppressed |
| Levofloxacin | Levofloxacin | 52 | 48 |
| Nitroglycerin | Nitroglycerin | 52 | 12 |
| Simvastatin | Simvastatin | 52 | 14 |
| Sucralfate | Sucralfate | 51 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 11 |
| Ondansetron Odt | Ondansetron | 50 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 23 |
| Bupropion Xl | Bupropion Hcl | 48 | 12 |
| Nabumetone | Nabumetone | 48 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 26 |
| Sertraline Hcl | Sertraline Hcl | 46 | 13 |
| Bumetanide | Bumetanide | 45 | suppressed |
| Levetiracetam | Levetiracetam | 45 | 15 |
| Megestrol Acetate | Megestrol Acetate | 45 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 45 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 33 |
| Fluconazole | Fluconazole | 43 | 29 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 42 | 16 |
| Olanzapine | Olanzapine | 41 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 41 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | suppressed |
| Cilostazol | Cilostazol | 38 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 37 | 11 |
| Finasteride | Finasteride | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Nystatin | Nystatin | 36 | 22 |
| Promethazine Hcl | Promethazine Hcl | 36 | 17 |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Naproxen | Naproxen | 34 | 18 |
| Tradjenta | Linagliptin | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Brilinta | Ticagrelor | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 29 |
| Gemtesa | Vibegron | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Indomethacin | Indomethacin | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 23 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Rybelsus | Semaglutide | 23 | suppressed |
| Ubrelvy | Ubrogepant | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Metronidazole | Metronidazole | 21 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Mitigare | Colchicine | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 17 |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Febuxostat | Febuxostat | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $379.11 · 22 records | Novo Nordisk Inc | Dexcom G6 Transmitter, FARXIGA, IBSRELA, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, Saxenda, Tresiba, VRAYLAR, Veozah, Wegovy, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error